These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521 [TBL] [Abstract][Full Text] [Related]
3. [Results with the use of the M-2 protocol in plasmacytoma]. Ho AD; Wittkamp S; Theml H; Keilholz U; Hunstein W Dtsch Med Wochenschr; 1986 May; 111(22):858-61. PubMed ID: 3754811 [TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205 [TBL] [Abstract][Full Text] [Related]
5. [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma]. Wutke K; Anger G Z Gesamte Inn Med; 1983 Dec; 38(23):630-3. PubMed ID: 6689459 [TBL] [Abstract][Full Text] [Related]
6. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039 [TBL] [Abstract][Full Text] [Related]
7. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol]. Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962 [TBL] [Abstract][Full Text] [Related]
8. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma. Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951 [TBL] [Abstract][Full Text] [Related]
9. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727 [TBL] [Abstract][Full Text] [Related]
10. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH; Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of multiple myeloma using vincristine, cyclophosphamide, melphalan and prednisone (VCMP). Long-term results in 63 patients]. Bladé J; Urbano A; López Guillermo A; Rozman M; Rovira M; Montserrat E; Rozman C Sangre (Barc); 1990 Apr; 35(2):93-7. PubMed ID: 2363100 [TBL] [Abstract][Full Text] [Related]
13. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Kyle RA; Leong T; Li S; Oken MM; Kay NE; Van Ness B; Greipp PR Cancer; 2006 May; 106(9):1958-66. PubMed ID: 16565956 [TBL] [Abstract][Full Text] [Related]
14. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma]. Le Loët X; Monconduit M; Menard JF; Deshayes P; Grobois B; Tanguy A; Prevost E; Piguet H Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189 [TBL] [Abstract][Full Text] [Related]
15. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Vela-Ojeda J; García-Ruiz Esparza MA; Rosas-Cabral A; Padilla-González Y; García-Chávez J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; García-León LD; Montiel-Cervantes L; Rubio-Borja ME Ann Hematol; 2002 Jul; 81(7):362-7. PubMed ID: 12185504 [TBL] [Abstract][Full Text] [Related]
16. [Recent therapy for refractory myeloma]. Togawa A Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332 [TBL] [Abstract][Full Text] [Related]
17. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness. Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662 [TBL] [Abstract][Full Text] [Related]
18. [The efficacy of polychemotherapy programs in treating multiple myeloma patients]. Bessmel'tsev SS; Abdulkadyrov KM; Rukavitsyn OA Ter Arkh; 1998; 70(7):46-9. PubMed ID: 9742636 [TBL] [Abstract][Full Text] [Related]
19. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Le Blanc R; Montminy-Métivier S; Bélanger R; Busque L; Fish D; Roy DC; Kassis J; Boileau J; Lavallée R; Bélanger D; Letendre F; Hébert J; Sauvageau G; Perreault C; Roy J Bone Marrow Transplant; 2001 Nov; 28(9):841-8. PubMed ID: 11781644 [TBL] [Abstract][Full Text] [Related]
20. [Combined treatment, polychemotherapy and amino-hydroxybutylidene-diphosphonate, of a patient with multiple myeloma: remission and long survival]. Attardo-Parrinello G; Merlini G; Crema F; Fiorentini ML; Mazzone A; Cotti-Piccinelli E Medicina (Firenze); 1988; 8(3):318-20. PubMed ID: 3231044 [No Abstract] [Full Text] [Related] [Next] [New Search]